First patients enrolled in record-breaking Ebola treatment trial in DRC
There is no approved drug to help the medical teams scrabbling to save lives in the Ebola outbreak in the Democratic Republic of the Congo – but there are hopes that could change within months as the…
Read the full articleYou might also wanna read
First patients enrolled in record-breaking Ebola treatment trial in DRC
Two drugs are being trialled in the Ituri region in a programme set up just six weeks after the outbreak was declared, with hopes it will re
First patients enrolled in record-breaking Ebola treatment trial in DRC
Two drugs are being trialled in the Ituri region in a programme set up just six weeks after the outbreak was declared, with hopes it will re
Experimental treatment trial for Ebola patients begins in Congo
The Democratic Republic of the Congo (DRC) has begun a groundbreaking clinical trial to test two experimental drugs for treating Ebola.
Clinical trials begin in DRC epicenter of Bundibugyo strain of Ebola
Clinical trials for treatments targeting the Bundibugyo strain of the Ebola virus disease began on July 2 in the Democratic Republic of Cong
Clinical trials begin in DRC epicenter of Bundibugyo strain of Ebola
Clinical trials for treatments targeting the Bundibugyo strain of the Ebola virus disease began on July 2 in the Democratic Republic of Cong
Trial of potential Ebola antiviral under way, says WHO
The first clinical trial is under way of an antiviral drug's effectiveness in people exposed to the deadly Ebola strain spreading in the Dem
Can fast, nimble clinical trials deliver a drug to halt the new Ebola outbreak?
One glimmer of hope in the Ebola response: Within hours of the outbreak in DRC being declared, researchers convened to prepare drug trials.
Congo begins trial of Gilead’s experimental antiviral for Ebola Bundibugyo
July 14 (Reuters) - Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial test
Comments
Sign in to join the conversation.
No comments yet. Be the first.